WGS250502P94000
- 29.70
- +26.85+942.11%
GeneDx Holdings Newsroom
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Cuts Target Price to $110
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Cuts Target Price to $100
GeneDx Holdings Price Target Cut to $110.00/Share From $135.00 by TD Securities
GeneDx Holdings Is Maintained at Buy by TD Securities
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Lowers Price Target to $78
GeneDx Holdings Analyst Ratings
Small U.S. Stocks Decrease; GeneDx Holdings Falls Furthest
GeneDx Holdings Corp. (WGS) Q1 2025 Earnings Call Transcript Summary
GeneDx Raises 2025 Revenue Guidance to $360M-$375M and Expands NICU Offerings
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
GeneDx Holdings Down Nearly 39%, On Pace For Record Percent Decrease -- Data Talk
S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Xencor (XNCR) and GeneDx Holdings (WGS)
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | GeneDx Shares Down 29.3% Premarket After Q1 Results
10-Q: Q1 2025 Earnings Report
8-K: GeneDx Reports First Quarter 2025 Financial Results and Business Highlights
Express News | GeneDx Holdings Corp Outlook Full Year Revenues Between $360 to $375 Mln
Express News | GeneDx Q1 Adjusted Net Income USD 7.7 Million